Please upgrade your browser.
Kidney Cancer Association (KCA) sponsors 12th annual medical meeting in Munich, Germany
A total of 462 patients were enrolled in the ADAPT study and randomized 2:1 between combination treatment with Rocapuldencel-T and sunitinib (combination arm) vs. sunitinib monotherapy (control arm).
Do high-risk clear cell renal cancer (ccRCC) (≥pT3 or node-positive) patients receiving adjuvant sunitinib or sorafenib have improved disease-free survival, and does the dose intensity of either drug affect outcome?
Between the frontline and second-line settings, there are multiple treatment options available for patients with renal cell carcinoma (RCC), but it is critically important for oncologists to decide on an agent with a patient’s characteristics—and goals—in mind, according to Eric Jonasch, MD.
The precise cause of kidney cancer is unknown, however the two main causes of kidney failure are diabetes and high blood pressure, which are responsible for more than 70 percent of all kidney failure cases. Therefore, kidney failure and disease can often be delayed or prevented...
Natural products possess enormous structural and chemical diversity and are a rich source of drugs or drug-like leads. Although the final products may not necessarily represent the active ingredients of the natural source, the majority of all drugs in the market have their origin in nature. Englerin A is guaiane sesquiterpene that was isolated from the Tanzanian plant Phyllanthus engleri and has attracted much attention because of its unique structure and cytotoxicity profile in cancer cells.
Argos Therapeutics Inc said on Wednesday that an independent data monitoring committee concluded that the company's experimental treatment for metastatic renal cell carcinoma would likely fail.
Your participation in this research project can help ensure that the company’s brochure and other materials are relevant to patients
In appreciation of your time and valuable contribution, you will receive an honorarium of $150 payable upon successful completion of the telephone interview.
Tumor ablation is a treatment that destroys cancerous tumors without removing them. This is done using a probe that utilizes thermal energy to heat or cool tumorigenic tissue to cytotoxic levels. Techniques such as computed tomography (CT), ultrasound (US), and magnetic resonance imaging (MRI) are used to guide and position the needle probe into the tumor. Tumor ablative techniques are used in patients having few tumors which are small in size.
Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma (RCC) were presented at ASCO GU 2017.
|Powered by NeonCRM|